Harbor is now

Sermorelin vs BPC-157: What Each Peptide Does & Which One Is Prescribed

Sermorelin is a prescription peptide with an FDA approval history. BPC‑157 has never been approved, and FDA and HHS both acted on it in 2026. Here is what each does and which one is prescribed.

Clinically reviewed
Medically reviewed by Harbor Health TeamMedical Content Team9 min read

At a glance

FDA and HHS records through November 13, 2026, plus published human studies
Prescribed peptide
Sermorelin vial

Sermorelin

GHRH analog, an Harbor program

  • TypeGHRH analog peptide
  • TargetPituitary gland
  • FDA statusNot FDA approved
  • Through HarborFrom $99 /mo, flat

BPC-157

Synthetic peptide, never approved

0Key numberFDA approvals for any use

  • Type15-amino-acid peptide
  • TargetNot identified
  • FDA statusNever approved
  • Through HarborNot offered

The verdict: Sermorelin has an FDA approval history, a known target in the pituitary and, through Harbor, a licensed clinician's review before it is prescribed. BPC-157 has never been approved, FDA's 2026 review found five human studies, and its compounding status rests on a draft federal policy dated October 30, 2026. Compounded sermorelin is not FDA approved.

Sermorelin vs BPC-157 verdict

On BPC 157 vs sermorelin, the deciding difference is the record behind each peptide. Sermorelin copies the active part of growth hormone-releasing hormone, and FDA approved it twice under the brand name Geref before its maker discontinued it. BPC-157 has no approved product in any country, according to FDA's 2026 review.

Sermorelin leads on the points that matter for a prescription: a known target in the pituitary, an approval history and, through Harbor, a licensed clinician's review before anything ships. Today's sermorelin is compounded, and compounded sermorelin is not FDA approved.

Online, BPC-157 has the bigger following and a long list of animal studies. Its human record is five studies, the largest with 53 people.

Popular, and still unproven.

Sermorelin vs BPC-157 side by side

Sermorelin vs BPC 157 comes down to four questions: what each one does, what human studies show, where each stands with FDA and how each is taken.

What each peptide does

Sermorelin works through one known pathway. A published review calls it the shortest synthetic peptide with the full biological activity of GHRH, and it acts on the anterior pituitary to release growth hormone (BioDrugs, 1999). It is not growth hormone. In the words of Harbor's sermorelin page, it "signals your pituitary gland to produce and release it in your body's own natural rhythm."

Ask what is BPC 157 used for, and the usual answer is injury recovery and gut health. In rodents, studies report effects such as healing of cut tendons and protection of the gut lining. FDA's reviewers found that its molecular targets have not been identified and that how it works remains poorly understood (FDA briefing document, 2026).

Many reported effects, and no confirmed target.

Evidence in humans

Documented sermorelin benefits in adults are mostly hormone measurements. In a 1992 National Institute on Aging study of 10 healthy older men, two weeks of twice-daily injections of GHRH 1-29, the sermorelin sequence, at the higher dose raised 24-hour growth hormone and IGF-1 to levels that no longer differed from young men (J Clin Endocrinol Metab, 1992). In a 1997 study of 11 men aged 64 to 76, six weeks of nightly injections raised overnight growth hormone release. IGF-1 did not change, two of six strength measures improved, and weight and scan measures of muscle and fat stayed the same (Metabolism, 1997).

Those adult studies are small, short and decades old. Sermorelin's approved treatment use was in children with growth hormone deficiency.

Claimed BPC 157 benefits rest mostly on animals. A 2025 systematic review found 36 studies published from 1993 to 2024, and 35 of them were preclinical (HSS Journal, 2025). That one clinical study was a chart review of knee injections in which 14 of 16 patients reported pain relief in a phone survey, with no comparison group (Altern Ther Health Med, 2021).

FDA's own 2026 search found five human studies in total, two of them published only as meeting abstracts. For ulcerative colitis, the one use it evaluated, FDA found a lack of evidence that BPC-157 works. ClinicalTrials.gov listed four registered BPC-157 studies on November 13, 2026, and none had posted results.

Healing in a rat is not yet proof in a person.

FDA status & legality

FDA approved sermorelin as Geref twice: in 1990 as a diagnostic test of pituitary function, and in 1997 to treat growth hormone deficiency in children with growth failure. Its maker discontinued both products in 2008, and in 2013 FDA determined they were not withdrawn for reasons of safety or effectiveness (Federal Register, 2013). Drugs@FDA lists both Geref products as discontinued and no other sermorelin product (Drugs@FDA).

Sermorelin prescribed today is a compounded drug, made for a patient on a prescription. Compounded drugs are not FDA approved, which means FDA does not verify their safety, effectiveness or quality before they are marketed (FDA).

For BPC-157, the record is shorter and busier. In September 2023, FDA placed it in Category 2, its group of nominated substances that raise significant safety risks in compounding (FDA). FDA removed it in an April 22, 2026 update after the nominators withdrew their requests. Its entry on the FDA compounding safety risk list remains, and it says the agency "lacks sufficient information to know whether the drug would cause harm when administered to humans."

FDA's reviewers then recommended against adding BPC-157 to the list of bulk substances that pharmacies may compound from (FDA briefing document, 2026). FDA's advisory committee took up BPC-157 on July 23, 2026, and HHS later reported that the committee voted in favor of adding it (HHS policy, 2026). That vote is advisory, and FDA had not posted minutes or a decision when this was written.

On October 30, 2026, the Department of Health and Human Services published a draft enforcement policy. Under it, HHS does not intend to act against state-licensed pharmacies or licensed physicians that compound with certain peptides while FDA's rulemaking continues (Federal Register, 2026). BPC-157 is one of six peptides on the policy's list, which also sets conditions for the pharmacy (HHS policy, 2026). According to the notice, the policy is not binding, was open for public comment for two weeks after publication, and may be revisited if a safety or quality problem appears.

As of November 13, 2026, BPC-157 is not FDA approved and is not on FDA's list of bulk substances for compounding (21 CFR 216.23). A compounded BPC-157 product would not be FDA approved either.

Tolerated for now is different from approved.

How each one is taken

Sermorelin has a defined routine. In the program's own words, it is "a self-administered subcutaneous injection at home, on a schedule your clinician sets for you." In the older pediatric trials it was given once a day at bedtime, and the post on how to take sermorelin walks through a nightly routine. Your clinician sets the dose.

With no approved BPC-157 product, no label sets a dose, a route or a schedule. FDA's review found it marketed as capsules, oral and nasal sprays and injections. That review found no human study of BPC-157 taken by mouth, injected under the skin, sprayed in the nose or applied to the skin. Published human reports used enemas, knee-joint injections, bladder injections and an IV infusion.

From FDA's 2026 briefing document and safety-risk page, the 2013 Federal Register notice on Geref, the October 30, 2026 HHS notice and published studies. Status as of November 13, 2026. Compounded sermorelin is not FDA approved.
AttributeSermorelinBPC-157
What it isFirst 29 amino acids of GHRH, a natural hormone signalSynthetic 15-amino-acid peptide, first reported in 1993
Where it actsThe pituitary gland, to release growth hormone Known targetMolecular target not identified, per FDA's 2026 review
FDA approval historyApproved as Geref in 1990 and 1997, discontinued in 2008 Approval historyNever approved in any country
Human studiesTrials in children plus small adult studies of hormone levels Longer recordFive, the largest with 53 people
Injury-repair researchIts trials measured growth hormone and growth in childrenRodent models of tendon, ligament, muscle and bone injury Animal data
FDA safety-risk listNot listed No FDA flagListed, with too little safety information on record
Compounding status, November 2026A compounded drug, made on a prescriptionNot on FDA's bulks list, covered by a draft HHS policy
Compounded productNot FDA approvedNot FDA approved
How it is takenInjection under the skin at home, on a schedule a clinician sets Set routineNo approved product, so no labeled dose or route
Through HarborFrom $99 a month, after a physician reviewNot an Harbor program

Scroll the table sideways to see both columns →

Who should choose sermorelin peptide therapy

Harbor sermorelin injections are built for adults seeking clinician-guided support for recovery, body composition, sleep and everyday vitality. A board-certified physician reviews your health history and goals before deciding whether treatment is appropriate for you.

Sermorelin may suit you when:

  • You want a medically guided approach to recovery and vitality
  • You are interested in supporting your body's own growth hormone
  • You want clinician support and monitoring along with the prescription
  • You are comfortable with a simple injection routine at home

Searches for sermorelin benefits for males have a narrow base to stand on. Both adult studies above enrolled only men, 10 in one and 11 in the other, and they measured hormone levels over weeks. A sermorelin program supports your body's own growth hormone release under clinician guidance rather than promising a specific result.

If you are weighing sermorelin and BPC 157 for an injury, neither one is an approved treatment for it. For a tear or a strain, a sports medicine or orthopedic clinician is the right first stop.

Use the review to mention anything else you take. One Harbor GLP-1 member, Leah Nadel, wrote in an August 20, 2026 Trustpilot review that she was "happy that a medical provider is available to answer any questions about my medical health that might interfere with the medication."

Sermorelin is not started without a physician review of your health history and goals, including any other peptides or medications you use. If a clinician does not approve treatment, the payment is refunded in full. For anything else, message your Harbor clinician.

Bottom line on sermorelin vs BPC-157

For now, "is BPC 157 legal" has no one-word answer.

BPC-157 is not an FDA-approved drug, and it is not on FDA's list of substances for compounding. A draft HHS policy says the department does not intend to act against licensed pharmacies and physicians that compound it under set conditions, and that policy can change.

Sermorelin stands on firmer ground. It was approved, it was not withdrawn from sale for safety or effectiveness reasons, and a licensed clinician can prescribe it today as a compounded medication, which is not FDA approved. For the same test applied to another peptide, see sermorelin vs CJC-1295 legality.

Through Harbor, a sermorelin program puts the medication, clinician care and check-ins in one flat monthly price, with licensed clinicians available around the clock for medical questions. If sermorelin is the peptide you want reviewed, the 90-second quiz starts a physician review.

This article is for general education and is not medical advice. It is not a substitute for evaluation, diagnosis, or treatment by a licensed clinician. Talk with a qualified clinician about your individual situation.

Harbor is a technology platform. Medical evaluations are conducted by independent, licensed healthcare providers who determine whether treatment is appropriate. Providers may prescribe FDA-approved or compounded medications based on clinical judgment and patient needs. Compounded medications are not FDA approved and are not reviewed by the FDA for safety or effectiveness.

Frequently asked questions

No. Asked plainly, "is BPC 157 FDA approved" gets a no for every use and every form. FDA's 2026 review found no approved product that contains BPC-157 in any country. October's draft HHS policy concerns pharmacy compounding and does not approve the peptide.

There is no evidence to guide that pairing. FDA's 2026 review identified five human BPC-157 studies, and none combined it with sermorelin. Sermorelin is an Harbor program and BPC-157 is not. If you already use BPC-157 or another peptide, say so at intake so the reviewing physician sees your full history.

No FDA-approved use exists for BPC-157. People mostly take it for injury recovery and gut complaints. FDA evaluated one use in 2026, ulcerative colitis, and found a lack of evidence that it works. Published human reports cover knee pain, a bladder pain condition and ulcerative colitis, each in a small group.

Sources

  1. U.S. Food and Drug Administration. FDA briefing document for BPC-157-related bulk drug substances, Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026 (evaluation dated May 11, 2026).
  2. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026).
  3. U.S. Food and Drug Administration. Bulk drug substances used in compounding under section 503A of the FD&C Act (content current as of May 14, 2026).
  4. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (content current as of August 6, 2026).
  5. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, notice of availability. 91 FR 68526 (October 30, 2026).
  6. 21 CFR 216.23. Bulk drug substances that can be used to compound drug products in accordance with section 503A. Electronic Code of Federal Regulations.
  7. Department of Health and Human Services. HHS enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances (draft), with Appendix A and Appendix B (October 2026).
  8. Federal Register. Determination that GEREF (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectiveness. 78 FR 14095 (March 4, 2013).
  9. U.S. Food and Drug Administration. Drugs@FDA: GEREF, NDA 020443.
  10. U.S. Food and Drug Administration. Compounding and the FDA: questions and answers (content current as of September 16, 2025).
  11. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157.
  12. Corpas E, et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535.
  13. Vittone J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96.
  14. Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485-495.
  15. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8-13.
  16. ClinicalTrials.gov. Registered studies with the intervention BPC-157 (searched November 13, 2026).